PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative
2002871
Ordering Recommendation
Provides genetic confirmation of APL. Predict relapse risk and monitor for minimal residual disease post-consolidation therapy.
Mnemonic
PML QNT
Methodology
Reverse Transcription Polymerase Chain Reaction
Performed
RNA isolation: Sun-Sat
Assay: Sun, Tue, Thu
Assay: Sun, Tue, Thu
Reported
2-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
- Patient Preparation
- Collect
- Lavender (EDTA) or bone marrow (EDTA).
- Specimen Preparation
- Transport 5 mL whole blood (Min: 1 mL). OR 3 mL bone marrow (Min: 1 mL). Specimens must be received within 48 hours of collection due to lability of RNA.
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.
- Remarks
- Stability
- Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable
Reference Interval
By report
Interpretive Data
Refer to report.
Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
This assay qualifies as COG approved for the AAML0631 study.
CPT Code(s)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2002872 | PML-RARA Translocation, t(15;17) | 21551-7 |
| 2002874 | PML-RARA Translocation, t(15;17) Quant | 21785-1 |
Aliases
- AMPL' APL
- APL MRD
- APL Post-consolidation therapy testing
- PML-RARA fusion types, A, B, B variant
- PML-RARA long, short, variable types
- PML-RARA S, L, V forms
- PML_RARA fusion types
- Quantitative PML
- t(15;17)